StockData
Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc. (INO) stock

INONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$1.63+0.23 (+16.43%)

Close on Nov 17, 2026Market cap $168.54MP/E –Yield –

Inovio Pharmaceuticals operating margin

Operating margin is operating income as a percentage of revenue.

Inovio Pharmaceuticals's operating margin for the twelve months ending Dec 31, 2025 was -132871.3%. For fiscal 2025 it was -132871.3%, against -51616.9% the year before. The highest annual figure on record is -84.5% in fiscal 2015.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-132871.3%−81254.4
FY2024Dec 31, 2024-51616.9%−34316.6
FY2023Dec 31, 2023-17300.3%−14692.9
FY2022Dec 31, 2022-2607.4%+14365.0
FY2021Dec 31, 2021-16972.3%−15298.1
FY2020Dec 31, 2020-1674.2%+1027.9
FY2019Dec 31, 2019-2702.1%−2393.4
FY2018Dec 31, 2018-308.7%−110.6
FY2017Dec 31, 2017-198.1%+17.4
FY2016Dec 31, 2016-215.5%−131.0
FY2015Dec 31, 2015-84.5%+293.2
FY2014Dec 31, 2014-377.7%−232.6
FY2013Dec 31, 2013-145.1%+425.3
FY2012Dec 31, 2012-570.4%−349.5
FY2011Dec 31, 2011-220.9%+91.9
FY2010Dec 31, 2010-312.8%−159.7
FY2009Dec 31, 2009-153.0%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2025Mar 31, 2025-38337.0%−29184.3
Q4 FY2024Dec 31, 2024-17410.8%−1018.8
Q2 FY2024Jun 30, 2024-32945.9%+5292.4
Q4 FY2023Dec 31, 2023-26686.3%+18190.5
Q3 FY2023Sep 30, 2023-9152.6%−8762.0
Q2 FY2023Jun 30, 2023-16392.0%−3115.8
Q1 FY2023Mar 31, 2023-38238.2%−2204.9
Q4 FY2022Dec 31, 2022-44876.8%−32303.1
Q3 FY2022Sep 30, 2022-390.6%+20162.5
Q2 FY2022Jun 30, 2022-13276.1%+17220.4
Q1 FY2022Mar 31, 2022-36033.3%−21872.3
Q4 FY2021Dec 31, 2021-12573.8%−12048.0
Q3 FY2021Sep 30, 2021-20553.2%−5170.9
Q2 FY2021Jun 30, 2021-30496.6%−18078.0
Q1 FY2021Mar 31, 2021-14161.1%−12260.0
Q4 FY2020Dec 31, 2020-525.7%+10358.8
Q3 FY2020Sep 30, 2020-15382.2%−12619.2
Q2 FY2020Jun 30, 2020-12418.6%+8367.2
Q1 FY2020Mar 31, 2020-1901.1%−892.7
Q4 FY2019Dec 31, 2019-10884.6%−9705.8
Q3 FY2019Sep 30, 2019-2763.0%−1431.5
Q2 FY2019Jun 30, 2019-20785.8%−20764.5
Q1 FY2019Mar 31, 2019-1008.3%+1132.4
Q4 FY2018Dec 31, 2018-1178.7%−918.3
Q3 FY2018Sep 30, 2018-1331.6%−227.9
Q2 FY2018Jun 30, 2018-21.3%+25.9
Q1 FY2018Mar 31, 2018-2140.8%−1929.4
Q4 FY2017Dec 31, 2017-260.5%+2.2
Q3 FY2017Sep 30, 2017-1103.6%−942.6
Q2 FY2017Jun 30, 2017-47.2%–
Q1 FY2017Mar 31, 2017-211.4%–
Q4 FY2016Dec 31, 2016-262.7%–
Q3 FY2016Sep 30, 2016-161.0%–

More Inovio Pharmaceuticals figures

See a number that looks wrong?